伴11q异常的伯基特样淋巴瘤的流式细胞免疫表型特征
流式细胞术显示前者CD16/CD56表达更常见(60% vs 0%)、CD8限制性表达(40% vs 4%),而后者CD38高表达(91% vs 10%)和CD45减弱(74% vs 10%)更频繁。CD16/CD56表达且无CD38高表达可快速鉴别11q异常,反之提示MYC重排。
要点
- 伴11q异常伯基特样淋巴瘤呈CD20+/CD10+/BCL6+/BCL2-/MUM1-/MYC+/EBV-,常LMO2+/CD44-/CD43-。
- 流式细胞术示CD16/CD56表达(60% vs 0%)和CD8限制性表达(40% vs 4%)多见于11q异常病例。
- CD38高表达(91% vs 10%)和CD45减弱(74% vs 10%)更常见于MYC阳性伯基特淋巴瘤。
核心结论
- 伴11q异常伯基特样淋巴瘤与MYC阳性伯基特淋巴瘤免疫表型相似但存在细微关键差异,有助于鉴别诊断和发病机制理解。
主要发现
- 免疫组化:所有伴11q异常病例均为CD20+/CD10+/BCL6+/BCL2-/MUM1-/MYC+/EBV-,常LMO2+/CD44-/CD43-,有时CD56+,增殖率高。
- 流式细胞术:CD38高表达在MYC阳性伯基特淋巴瘤更常见(91% vs 10%,调整P<0.001),CD45减弱也更常见(74% vs 10%)。
- CD16/CD56表达(60% vs 0%)和CD8限制性表达(40% vs 4%)仅见于伴11q异常伯基特样淋巴瘤。
- 伴11q异常伯基特样淋巴瘤患者80%获得5年无复发生存。
- 确认11q倒位重复伴端粒丢失为复发性11q异常,但一例呈现替代性改变可能产生等效分子效应。
关键数值与推荐
- CD16/CD56表达且无CD38高表达提示11q异常;无CD16/CD56且CD38高表达提示MYC重排。
- 调整P<0.001(CD38高表达比较),CD16/CD56表达60% vs 0%,CD8表达40% vs 4%,CD45减弱74% vs 10%。
临床怎么用
- 流式细胞术检测CD16/CD56、CD38和CD45表达可快速、经济地辅助鉴别伴11q异常伯基特样淋巴瘤与MYC阳性伯基特淋巴瘤。
局限性
- 样本量较小(实验组10例),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We previously described a subset of MYC translocation-negative aggressive B-cell lymphomas resembling Burkitt lymphoma, characterized by proximal gains and distal losses in chromosome 11. In the 2016 WHO classification, these MYC-negative lymphomas were recognized as a new provisional entity, 'Burkitt-like lymphoma with 11q aberration'. Here we present an immunophenotype analysis of Burkitt-like lymphomas with 11q aberration. Cells were acquired by fine needle aspiration biopsy from 10 young adult patients, 80% of whom presented recurrence-free 5-year survival. Twenty-three MYC-positive Burkitt lymphomas, including three carrying both MYC rearrangement and 11q aberration, served as controls. By immunohistochemistry, all Burkitt-like lymphomas with 11q aberration were CD20+/CD10+/BCL6+/BCL2-/MUM1-/MYC+/EBV-, usually LMO2+/CD44-/CD43- and sometimes CD56+, and showed high proliferation rate. By flow cytometry, Burkitt-like lymphoma with 11q aberration immunophenotypically resembled MYC-positive Burkitt lymphoma, except for significantly (adjusted P<0.001) more frequent CD38higher expression in Burkitt lymphoma (91% MYC-positive Burkitt lymphoma vs 10% Burkitt-like lymphoma with 11q aberration), more frequently diminished CD45 expression in Burkitt lymphoma (74% vs 10%), an exclusive CD16/CD56 and highly restricted CD8 expression in Burkitt-like lymphoma with 11q aberration (60% vs 0% and 40% vs 4%, respectively). We showed high diagnostic accuracy and effectiveness of flow cytometry in Burkitt lymphoma. CD16/CD56 expression without CD38higher and the lack of CD16/CD56 with CD38higher expression proves to be a reliable, fast, and cost-effective method for diagnosing 11q aberration and MYC rearrangements in CD10(+) aggressive lymphomas, respectively. In addition, we confirmed a pattern of an inverted duplication with telomeric loss of 11q, as a recurrent 11q abnormality, but one case presented alternative changes, possibly resulting in an equivalent molecular effect. Our findings reveal similarities along with subtle but essential differences in the immunophenotype of Burkitt-like lymphoma with 11q aberration and MYC-positive Burkitt lymphoma, important for the differential diagnosis, but also for understanding the pathogenesis of Burkitt-like lymphoma with 11q aberration.
引用
- Rymkiewicz G, Grygalewicz B, Chechlinska M, et al. A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. Mod Pathol. 2018. PMID: 29327714. doi:10.1038/modpathol.2017.186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。